Oral vs Sublingual Ketamine: Tablets, Troches, and How They Compare

Overview

When patients hear about "oral ketamine," the term can be confusing because it is used to describe two distinct methods of taking the medication by mouth — sublingual administration (held under the tongue for absorption through the oral mucosa) and oral administration (swallowed and absorbed through the gastrointestinal tract). Though both involve putting ketamine in your mouth, they work quite differently in your body, and understanding the distinction matters for your treatment.

Most at-home ketamine therapy programs prescribe sublingual formulations, but oral forms are also used in certain contexts. This comparison clarifies the practical differences so you know what to expect. For a firsthand account of what sublingual sessions are like, read about the oral ketamine experience.

How Each Method Works

Sublingual Ketamine

Sublingual ketamine comes in the form of troches (rhymes with "roach-ees") — soft, waxy lozenges — or rapidly dissolving tablets (RDTs). You place the medication under your tongue or between your cheek and gum, where it dissolves over 10 to 15 minutes. The ketamine is absorbed directly through the mucous membranes of your mouth into the bloodstream, partially bypassing the liver and its first-pass metabolism.

Key point: You are instructed to hold the dissolved medication in your mouth as long as possible (often 10 to 15 minutes) before swallowing any remaining liquid. The longer the contact with the oral mucosa, the more ketamine is absorbed sublingually. Some protocols instruct patients to spit out any remaining liquid rather than swallow it to minimize GI side effects.

Oral Ketamine (Swallowed)

Oral ketamine typically comes as a capsule or liquid solution that is swallowed. The medication travels to the stomach and small intestine, where it is absorbed into the bloodstream and transported to the liver via the portal circulation. In the liver, a significant portion of the ketamine is converted to norketamine through first-pass metabolism before reaching systemic circulation.

Key point: Norketamine is an active metabolite with its own pharmacological effects, including some antidepressant activity, but it is less potent than ketamine itself at NMDA receptors. The higher proportion of norketamine in oral (swallowed) ketamine may contribute to a different subjective experience compared to sublingual administration.

Bioavailability Comparison

Bioavailability is the percentage of the administered drug that reaches systemic circulation in its active form. This is the most important pharmacological difference between the two routes:

The nearly twofold difference in bioavailability means that sublingual administration delivers meaningfully more active ketamine to the brain per milligram of medication administered. This translates to more predictable and consistent therapeutic plasma levels.

Effectiveness

Sublingual Ketamine

The higher bioavailability of sublingual ketamine makes it the preferred oral route for therapeutic purposes. It produces plasma levels that more closely approximate (though still fall below) those achieved with IV or IM administration. Most of the clinical evidence supporting at-home ketamine therapy programs comes from sublingual protocols.

Patients using sublingual ketamine typically experience:

• More pronounced dissociative effects (therapeutic range)
• More consistent session-to-session experiences
• Better alignment with the evidence base from clinical studies

Oral Ketamine (Swallowed)

Oral ketamine is sometimes prescribed for chronic pain management, where lower and more sustained plasma levels may be desirable. For psychiatric indications, the lower and more variable bioavailability means that achieving consistent therapeutic levels is more challenging. Some providers use oral ketamine for maintenance therapy or for patients who find the dissociative effects of sublingual ketamine too intense.

Patients using oral (swallowed) ketamine may experience:

• Milder dissociative effects
• More gradual onset and longer duration
• Greater variability between sessions depending on stomach contents and other factors
• Potentially more GI side effects (nausea, stomach discomfort)

Side Effects

Sublingual Ketamine

Common side effects include:

• Dissociation (typically within the therapeutic range when properly dosed)
• Numbness or tingling in the mouth from direct mucosal contact
• Nausea (less common than with oral administration because less medication passes through the GI tract)
• Bitter taste (ketamine has a notably bitter flavor)
• Dizziness and lightheadedness
• Temporary blood pressure elevation

The bitter taste is frequently cited as the most unpleasant aspect of sublingual administration. Some compounding pharmacies add flavoring to troches to mitigate this, with varying success.

Oral Ketamine (Swallowed)

Common side effects include:

• Nausea and stomach discomfort (more common due to GI absorption)
• Milder dissociation
• Dizziness
• Drowsiness (may be more pronounced due to higher norketamine levels)
• Temporary blood pressure elevation (typically less pronounced)

The higher rate of GI side effects with oral administration is a significant practical consideration. Nausea can be managed with anti-nausea medication taken before the session, but it adds complexity to the treatment routine. Our guide to managing side effects covers practical strategies for dealing with nausea and other common issues.

Practical Considerations

Sublingual Administration Tips

Getting the most out of sublingual ketamine requires technique:

1. Do not eat for four to six hours before your session to reduce nausea risk
2. Place the troche under your tongue or in your cheek pocket — do not chew or swallow it
3. Let it dissolve completely over 10 to 15 minutes, gently moving the dissolved liquid around your mouth
4. Minimize swallowing during the absorption period
5. Some protocols say to spit; others say to swallow the remaining liquid — follow your provider's specific instructions
6. Lie down in a comfortable position once you have placed the medication, and remain still throughout your session

Oral Administration Tips

1. Take the medication on an empty stomach for more consistent absorption
2. Have anti-nausea medication available (your provider can prescribe ondansetron or recommend over-the-counter options)
3. Expect a slower onset — do not take additional medication if effects are not immediate
4. Plan for a longer session duration than sublingual protocols

Which Is Used in At-Home Programs?

The vast majority of at-home ketamine therapy programs prescribe sublingual formulations. The higher bioavailability, more predictable onset, and better alignment with the clinical evidence make sublingual the standard choice for therapeutic purposes.

If your provider prescribes an oral (swallowed) formulation, ask why they chose this route over sublingual and whether sublingual might be more appropriate for your situation. There may be a good reason — for example, if you have had difficulty tolerating the dissociative effects of sublingual ketamine, or if you are being treated for a pain condition where sustained lower levels are preferred.

Compounding Quality Matters

Both sublingual troches and oral formulations are prepared by compounding pharmacies rather than manufactured by large pharmaceutical companies. The quality and consistency of compounded medications can vary between pharmacies. Your provider should use a reputable, accredited compounding pharmacy (look for PCAB accreditation or state board of pharmacy licensing) to ensure that your medication is accurately dosed and properly formulated.

References

• Andrade C. Oral ketamine for depression. Journal of Clinical Psychiatry, 2019. — Evidence review covering oral and sublingual ketamine for depression
• Greenway KT, et al. Ketamine pharmacokinetics by route of administration. Canadian Journal of Anesthesia, 2021. — Detailed pharmacokinetic comparison of ketamine routes including oral and sublingual
• Schoevers RA, et al. Oral ketamine for the treatment of pain and treatment-resistant depression. British Journal of Psychiatry, 2016. — Clinical review of oral ketamine's therapeutic applications
• Peltoniemi MA, et al. Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clinical Pharmacokinetics, 2016. — Comprehensive pharmacokinetic reference for all ketamine routes
• Compounding quality and safety. U.S. Food & Drug Administration. — FDA guidance on compounding pharmacy standards and regulations